Tipifarnib and farnesyltransferase inhibitors in the treatment of inflammatory breast cancer: is the story over? A review

摘要: Inflammatory breast cancer (IBC) is a rare but aggressive form of with unique clinicopathological features and poor prognosis. Its epidemiology distinct from noninflammatory locally advanced (LABC), which points to different etiology. With the advent multimodality treatment for LABC, outcomes women IBC have improved, remain significantly inferior LABC. This review focuses on new research in molecular pathways characteristic IBC. One critical carcinogenic events apparently driving development progression activation RhoC protein, part Ras oncogene superfamily. These proteins, like other require posttranslational prenylation their transfer cell membranes. Farnesylation common type prenlyation that can be blocked class drugs - farnesyltransferase inhibitors. The most inhibitor development, tipifarnib, has been evaluated Phase II clinical trials as monotherapy combination antihormonal agents trastuzumab metastatic cancer. A few tumor responses observed these trials, not enough warrant III trial. Potential combinations tipifarnib novel targeting enzymes downstream are reviewed. Some drugs, such imatinib crizotinib, already commercially available. Others perifosine anti-vascular endothelial growth factor 3 antibody currently under development. Innovative trial designs address this discussed.